Research programme: monoclonal antibody therapeutics - Kymab

Drug Profile

Research programme: monoclonal antibody therapeutics - Kymab

Alternative Names: KY 1003; KY 1005; KY 1006; KY 1007; KY 1009; KY 1015; KY 1016; KY 1017; KY 1020; KY 1021; KY 1031; KY 1034; KY 1040; KY 1041; KY 1043; KY 1044; KY 1047; KY 1050; KY 1055; KY 7001; KY 7002; KY 7003; KY 7004; KY 7005; KY 7006

Latest Information Update: 04 Jan 2017

Price : $50

At a glance

  • Originator Kymab
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inflammatory bowel diseases
  • Research Cancer; Haematological disorders; Systemic lupus erythematosus
  • Discontinued Cardiovascular disorders; Dyslipidaemias; Fibrosis; Graft-versus-host disease; Infections; Pain

Most Recent Events

  • 04 Jan 2017 Discontinued - Preclinical for Graft-versus-host disease in United Kingdom (Parenteral)
  • 04 Jan 2017 Discontinued for Cardiovascular disorders in United Kingdom (Parenteral)
  • 04 Jan 2017 Discontinued for Dyslipidaemias in United Kingdom (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top